Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±¾ÏÀÇ Áø´Ü¿¡¼­ ÃÑ Àü¸³¼± ƯÀÌ Ç׿øÄ¡¿¡ ´ëÇÑ À¯¸®Çü Àü¸³¼± ƯÀÌ Ç׿øÄ¡ ºñÀ²ÀÇ ÀÇÀÇ The Value of Free/Total Prostate Specific Antigen Ratio in the Diagnosis of Prostate Cancer

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 5È£ p.459 ~ 463
¼Õ¹®°©, ±èÇö¼ö, ¿ÀÅÂÈñ,
¼Ò¼Ó »ó¼¼Á¤º¸
¼Õ¹®°© (  ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

±èÇö¼ö (  ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
¿ÀÅÂÈñ (  ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
Ç÷û Àü¸³¼±Æ¯ÀÌÇ׿ø(prostate specific antigen, PSA)ÀÌ ÀÓ»ó¿¡ µµÀÔµÈ ÀÌÈÄ'Àü¸³¼±¾ÏÀÇ
Áø´Ü ¹× Ä¡·á ÈÄ È¿°ú ÆÇÁ¤°ú ÃßÀû°Ë»ç¿¡ Áß¿äÇÑ ÁöÇ¥·Î »ç¿ëµÇ°í ÀÖÀ¸¸ç ƯÈ÷ Àü¸³¼±¾ÏÀÇ
Á¶±â¹ß°ßÀ» À§ÇÏ¿© Ç÷û PSA´Â Á÷Àå ¼öÁö°Ë»ç, Á÷ÀåÃÊÀ½ÆÄ°Ë»ç ¹× Á¶Á÷°Ë»ç¿Í ´õºÒ¾î ¸¹ÀÌ
ÀÌ¿ëµÇ°í ÀÖ´Ù. ±×·¯³ª Ç÷û PSA´Â Àü¸³¼±¾Ï¿¡¼­¸¸ ƯÀÌÀûÀ¸·Î Áõ°¡ÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó Àü¸³
¼±ºñ´ëÁõ, Àü¸³¼±¿°Áõ¼ºÁúȯ, ¿äµµ ±â±â »ç¿ë ½Ã¿¡¼­µµ Áõ°¡ÇÒ ¼ö°¡ À־ ¼±º°°Ë»ç·Î¼­ÀÇ
°¡Ä¡°¡ ¶³¾îÁú ¼ö ÀÖ´Ù. ÃÖ±Ù ÀÌ·¯ÇÑ ¹®Á¦Á¡À» ±Øº¹ÇÏ°í Ç÷û PSAÀÇ Àü¸³¼±¾Ï Áø´Ü¿¡ ´ëÇÑ
¹Î°¨µµ¿Í ƯÀ̵µ¸¦ ³ô¿©, ºÒÇÊ¿äÇÑ Á¶Á÷°Ë»ç¸¦ ÁÙÀÌ·Á´Â ³ë·ÂÀ¸·Î ¿¬·É¿¡ µû¸¥ PSAÄ¡, Àü
¸³¼±Æ¯ÀÌÇ׿ø¹Ðµµ(PSA density, PSAD)¿Í Àü¸³¼±Æ¯ÀÌÇ׿ø¼Óµµ(PSA, velocity)ÀÇ °³³äÀ» µµ
ÀÔÇÏ¿´°í ÃÖ±Ù¿¡´Â Ç÷û PSAÀÇ ºÐÀÚÇüÅÂ(molecular forms), Áï °áÇÕÇü(comp18xed form)°ú
À¯¸®Çü(See form) PSAÀÇ Á¸Àç°¡ ¹àÇôÁ® ÃÑPSAÄ¡¿¡ ´ëÇÑ À¯¸®Çü PSAÄ¡ÀÇ ºñÀ²(free to
total PSA ratio, F/T ratio)ÀÌ Àü¸³¼±¾ÏÀÇ Áø´Ü¿¡ µµ¿òÀÌ µÈ´Ù°í ÇÏ¿© È°¹ßÇÑ ¿¬±¸°¡ ÀÌ·ç
¾îÁö°í ÀÖ´Ù. ÀúÀÚµéÀº Àü¸³¼±¾Ï ȯÀÚ¿Í Àü¸³¼±ºñ´ëÁõ ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿© F/T ratio¸¦
ÃøÁ¤ÇÏ¿© ÃÑPSA¸¸À¸·Î °Ë»çÇßÀ» ¶§º¸´Ù Àü¸³¼±¾Ï Áø´Ü¿¡ ´ëÇÑ ¼±º°°Ë»ç·Î¼­ ÀÇÀǸ¦ ¾Ë¾Æ
º¸°íÀÚ ÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose: We investigated the value of the free to total PSA ratio of intermediate
serum PSA levels(4-20ng/m1) in the detection of prostate cancer.
Materials and Methods: Free PSA, total PSA levels and free to total PSA ratio(F/T
ratio) were measured on sera samples of 103 men with symptomatic BPH and 20 men
with prostate cancer, who were proved by biopsy, by using ELSA-PSA2 and
FPSA-RIACT. And we used transrectal ultrasound determined prostate volume to
calculated PSA density(PSAD).
Results: In all patients, mean PSAD was significantly greater for patients with
cancer(2.07¡¾ 1.65) versus BPH(0.12¡¾0.12). The F/T ratio was significantly lower for
cancer(0.12¡¾0.04) compared with BPH(0.32¡¾0.20). At a time, when serum PSA between
4 and 20ng/m1 was considered in 8 patients with cancer and 38 patients with BPH,
mean total serum PSA was significantly greater for patients with cancer(12.02¡¾
3.54ng/m1) versus BPH(7.21 ¡¾3.68ng/m1). Mean PSAD was significantly greater for
patients with cancer(0.36¡¾ 0.12) versus BPH(0.20¡¾0.12) and the F/T ratio was
significantly lower for cancer(0.14¡¾0.03) compared with BPH(0.25¡¾0.12). Use of the Ff
ratio of 0.15 resulted in the highest sensitivity(75%) and specificity(89.5%) and the F/T
ratio was superior to total PSA when compared with receiver operating characteristic
curve .
Conclusions: The F/T ratio give a significant improvement over total PSA value in
the diagnosis of prostate cancer in patients with intermediate PSA levels. But, to assess
accurately usefullness of F/T ratio in early prostate cancer detection, further studies are
needed and consensual threshold value is necessary. (Korean J Urol 1998; 39: 459¡­63)

Å°¿öµå

Prostate cancer; Diagnosis; Free to total PSA ratio;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS